Shenwan Hongyuan has released a research report forecasting that BIOCYTOGEN-B (02315) will achieve net profits attributable to the parent company of 423 million, 661 million, and 956 million yuan for the years 2026 to 2028, representing year-on-year growth rates of 144.07%, 56.3%, and 44.68% respectively. Based on the company's sector and primary business, comparable firms such as Zhaoyan New Drug, Chengdu Lead Science & Technology, and Yao Kang Biology were selected for analysis. The current share price implies a price-to-earnings ratio of 38 times for 2026. Applying an average 2026 P/E multiple of 47 times, the corresponding market capitalization would be 228 billion Hong Kong dollars. With a current market cap of 183 billion HKD, this suggests an upside potential of approximately 24.5%. Consequently, the firm has initiated coverage with a "Buy" rating.
Key Investment Thesis
Innovation Platform Reaches Critical Mass, Post A+H Listing Enters Accelerated Value Realization Phase
After over a decade of development, Biocytogen has evolved into an international biotechnology company integrating four core platforms: genetically engineered model animal generation, model animal breeding and supply, preclinical pharmacological efficacy evaluation, and antibody drug discovery. From 2022 to 2025, its revenue demonstrated a compound annual growth rate of 37.2%. The company achieved its first annual profit in 2024 and reported a net profit attributable to the parent of 173 million yuan in 2025, marking its entry into a period of profit release. The company's core business axis revolves around the dual drivers of model animals and its "Thousand Mice Ten Thousand Antibodies" initiative. With deep market penetration both domestically and internationally, supported by its closed-loop technology, data moat, global footprint, and AI enablement, Biocytogen is positioned to grow into a globally leading platform for antibody drug source innovation.
Industry Demand Continues to Expand, Favorable Trends in Preclinical CRO and Model Mouse Sectors
The Chinese preclinical CRO market is experiencing sustained expansion, with its scale reaching 40.58 billion yuan in 2023 and projected to grow to 89.93 billion yuan by 2030. The model mouse segment remains highly active, with industry competition shifting towards comprehensive capabilities in model variety, breeding capacity, and more. As of the end of 2025, Biocytogen had internally developed approximately 5,000 genetically edited animal and cell models, including over 2,000 target-humanized mouse models. The company has established animal centers spanning 55,000 square meters in Beijing and Haimen, creating an integrated barrier encompassing "model development - breeding - efficacy validation." The company's model animal and preclinical CRO businesses have maintained robust growth for years and have established deep, close partnerships with leading global innovative pharmaceutical companies. This high barrier, coupled with favorable industry tailwinds, positions the company for continued market share gains.
AI-Enhanced RenMice Platform Accelerates Antibody Business Value Realization
Leveraging its fully human antibody RenMice platform and the "Thousand Mice Ten Thousand Antibodies" project, as of December 31, 2025, the company had completed evaluation and research on approximately 1,200 targets and had essentially initiated antibody development for all targets. This effort has generated a "shelf" of over one million antibody molecule sequences with rich epitope diversity. From 2022 to 2025, the antibody business grew at a CAGR of 37.8%, with gross margins consistently above 85%. In May 2026, the company launched its next-generation AI platform, RenSuper, which enables intelligent and automated antibody screening, significantly improving efficiency. The convergence of AI empowerment, licensing/partnership conversions, and high-margin monetization is driving continuous value realization from the platform, highlighting its substantial growth potential.
Potential Risk Factors
The report highlights several risks, including the pace of technological upgrades and iterations, risks associated with overseas operations and currency exchange rate fluctuations, the potential for animal models to fail to meet client requirements, and the risk of antibody development falling short of expectations.
Comments